The Cambridge RNAi developer sold 11.1 million shares at the midpoint of its range. Its lead drug, a Factor XI siRNA for blood clots, has more phase 1 data due in late 2026.
Latest City Therapeutics news
We have not published a story on City Therapeutics yet. When there is news, it will appear here.
Questions about City Therapeutics
When did City Therapeutics go public?
Our latest story on this, dated Oct 16, 2026: "City Therapeutics raises $200 million in upsized IPO priced at $18". The story links the filing or release it is based on. Read the story.
Has City Therapeutics raised money recently?
Our latest story on this, dated Oct 16, 2026: "City Therapeutics raises $200 million in upsized IPO priced at $18". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of City Therapeutics?
City Therapeutics, Inc. trades under the ticker CTY on NASDAQ.
Where is City Therapeutics listed?
City Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of City Therapeutics?
The SEC Central Index Key (CIK) for City Therapeutics, Inc. is 2143850. Its filings are on SEC EDGAR.
Which country or territory is City Therapeutics listed under?
Our directory records City Therapeutics, Inc. under United States.
What does City Therapeutics do?
Our directory classifies City Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of City Therapeutics?
The ISIN recorded for City Therapeutics, Inc. is US1787821081.
Does aibio.space cover City Therapeutics?
aibio.space lists City Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is City Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest City Therapeutics (CTY) stock news?
Our latest story on City Therapeutics, dated Oct 16, 2026: "City Therapeutics raises $200 million in upsized IPO priced at $18". The Cambridge RNAi developer sold 11.1 million shares at the midpoint of its range. Its lead drug, a Factor XI siRNA for blood clots, has more phase 1 data due in late 2026. Source.
Is City Therapeutics a smaller reporting company?
SEC records list City Therapeutics, Inc.'s filer category as: <br>Emerging growth company.
Where is City Therapeutics headquartered?
SEC records list its business address as 399 BINNEY ST, CAMBRIDGE, MA, 02141.
When does City Therapeutics's fiscal year end?
City Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records.
What did City Therapeutics last file with the SEC?
Its most recent filing in our record is an 8-K filed 2026-10-19. All of its filings are on SEC EDGAR. Source.
Investor discussion: City Therapeutics
Members talk about City Therapeutics (CTY). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at City Therapeutics, newest first. Each line links the filing it comes from.
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CTY on TradingView.
SEC filings and registration
SEC name
City Therapeutics, Inc.
CIK
2143850
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
CTY (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
399 BINNEY ST, CAMBRIDGE, MA, 02141
Phone
857-357-2024
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
City Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CTY, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio